Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Nurix Therapeutics (NRIX) Net Margin: 2019-2025

Historic Net Margin for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -1,094.77%.

  • Nurix Therapeutics' Net Margin fell 70586.00% to -1,094.77% in Q3 2025 from the same period last year, while for Aug 2025 it was -292.50%, marking a year-over-year increase of 2115.00%. This contributed to the annual value of -354.85% for FY2024, which is 16788.00% down from last year.
  • Per Nurix Therapeutics' latest filing, its Net Margin stood at -1,094.77% for Q3 2025, which was down 1,009.68% from -98.66% recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Net Margin high stood at -79.14% for Q2 2023, and its period low was -1,094.77% during Q3 2025.
  • Moreover, its 3-year median value for Net Margin was -305.38% (2025), whereas its average is -347.68%.
  • In the last 5 years, Nurix Therapeutics' Net Margin soared by 41,196bps in 2023 and then slumped by 70,586bps in 2025.
  • Over the past 5 years, Nurix Therapeutics' Net Margin (Quarterly) stood at -509.59% in 2021, then tumbled by 17,915bps to -688.74% in 2022, then surged by 41,196bps to -276.77% in 2023, then plummeted by 16,398bps to -440.75% in 2024, then slumped by 70,586bps to -1,094.77% in 2025.
  • Its last three reported values are -1,094.77% in Q3 2025, -98.66% for Q2 2025, and -305.38% during Q1 2025.